• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RASAGILINE Drug Record

  • Summary
  • Interactions
  • Claims
  • RASAGILINE chembl:CHEMBL887 Approved

    Alternate Names:

    TV-1030
    AGN-1135
    RASAGILINE
    AZILECT
    (1R)-N-PROPARGYLINDAN-1-AMINE
    (R)-INDAN-1-YL-PROP-2-YNYL-AMINE
    (R)-N-2-PROPYNYL-1-INDANAMINE
    RAS
    TVP-1012
    AZILECT®
    chembl:CHEMBL887
    chemidplus:136236-51-6
    rxcui:134748
    pubchem.compound:3052776
    drugbank:01367

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antiparkinson agent
    Drug Class antiparkinson agents
    Year of Approval 2006
    (1 More Sources)

    Publications:

    Chau et al., 2010, Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells., Neurochem. Int.
    Uzun et al., Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits., Eur Rev Med Pharmacol Sci
    Weinreb et al., 2010, Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity., Prog. Neurobiol.
    Chen et al., 2007, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease., Clin Ther
    Youdim et al., Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition., J. Neurosci. Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Naoi et al., 2009, Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease., Expert Rev Neurother
    Leegwater-Kim et al., 2010, The role of rasagiline in the treatment of Parkinson's disease., Clin Interv Aging
    Youdim et al., 2001, Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]., Cell. Mol. Neurobiol.
    Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain
  • RASAGILINE   MAOB

    Interaction Score: 8.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name rasagiline mesylate, TVP-1012,Agilect
    Novel drug target Established target

    PMIDs:
    20624440 19499843 20600573 18035186 15573406 11752352 19673610 20517484 12043833


    Sources:
    TdgClinicalTrial TEND TTD

  • RASAGILINE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27190009


    Sources:
    PharmGKB

  • TEND: RASAGILINE

    • Version: 01-August-2011

    Alternate Names:
    RASAGILINE Primary Drug Name

    Drug Info:
    Year of Approval 2006
    Drug Class antiparkinson agents

    Publications:

  • TdgClinicalTrial: RASAGILINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiparkinson agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: rasagiline

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain

  • TTD: Rasagiline

    • Version: 2020.06.01

    Alternate Names:
    D06OMW TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL887

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21